Compare BridgeBio Pharma Inc (BBIO) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marriott International Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Marriott International Inc trades at $349.88 (market cap $91.14B). The key difference: Marriott International Inc is far larger — about 5.6× BridgeBio Pharma Inc's market cap, and Marriott International Inc pays a 0.84% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MAR | |
|---|---|---|
Market Cap | $16.36B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $402.54 |
52-Week Low | $47.29 | $259.04 |
Enterprise Value | $18.14B | $108.45B |
Dividend Yield | — | 0.84% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
